Qiagen posts strong Q2, raises 2025 sales outlook

Published 05/08/2025, 21:28

Investing.com -- Qiagen (NYSE:QGEN) reported strong second-quarter result, driven by strong demand for its diagnostic solutions and improved profitability, and raised its full-year sales outlook.

Net sales rose 7% to $534 million, or 6% at constant exchange rates (CER), beating its prior guidance for at least 5% CER growth.

Adjusted diluted EPS came in at $0.60, also ahead of the company’s target of at least $0.60 CER.

Qiagen said adjusted operating income margin improved to 29.9%, up 1.5 percentage points from the year-ago period.

Growth was led by an 11% CER increase in diagnostic solutions, supported by a 41% jump in QIAstat-Dx sales and 11% growth in QuantiFERON, along with gains in companion diagnostics.

The company now expects full-year net sales growth of 4–5% CER, up from about 4% previously. It maintained its adjusted EPS outlook of approximately $2.35 CER.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.